Consensus CorMedix Inc.

Stocks

CRMD

US21900C3088

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 23/10/2026 +03			5-day change	1st Jan Change
7.850 ^USD	-3.09%		+8.13%	-32.50%

10-20	CorMedix Therapeutics Announces FDA Acceptance For Priority Review Of Supplemental NDA For REZZAYO® For Prophylaxis Of Invasive Fungal Diseases	CI
10-19	CorMedix Receives FDA Priority Review for Rezzayo Fungal Disease Prevention	MT

Evolution of the Average Target: CorMedix Inc.

Evolution of the Target Price: CorMedix Inc.

Changes in Analyst Recommendations: CorMedix Inc.

df5b34b37779606e4c.cYFwCFfffw1aN3ACcdeGmYBusBmZ4wfu5A4Wr0gBm84.NeUEfjavCVQccUEwG6bj2OE85VfKhV2_tVFkmTpG7ZFJ5TheLb4pVzJkBw~66a6ef644815690f19dfc9d1d54d26d2

Analysts' recommendations: CorMedix Inc.

09-23	Oppenheimer Initiates CorMedix at Outperform With $15 Price Target	MT
08-14	CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says	MT
08-14	RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating	MT
07-07	RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating	MT
04-28	RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk	MT
02-11	CorMedix's Growth Outlook Hinges on Trial Data, Prophylaxis Opportunity, RBC Says	MT
01-21	RBC Cuts Price Target on CorMedix to $13 From $22, Keeps Outperform, Speculative Risk	MT
21/10/25	RBC Lifts Price Target on CorMedix to $22 From $21, Keeps Outperform, Speculative Risk	MT
20/10/25	Biopharma firm CorMedix beats Q3 revenue estimates, raises FY guidance	RE
20/10/25	CorMedix Inc. Announces Unaudited Preliminary Revenue Results for the Third Quarter of 2025	CI
29/09/25	Cormedix announces completion of enrollment in phase III Respect clinical trial for Rezzayo	RE
07/07/25	RBC Lifts Price Target on CorMedix to $18 From $17, Keeps Outperform, Speculative Risk	MT
30/06/25	HC Wainwright Initiates Coverage on CorMedix With Buy Rating, $20 Price Target	MT
23/06/25	Needham Raises CorMedix's Price Target to $20 from $15, Keeps Buy Rating	MT
20/06/25	RBC Adjusts Price Target on CorMedix to $17 From $13, Maintains Outperform, Speculative Risk Rating	MT
25/03/25	Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating	MT
07/03/25	Leerink Partners Initiates CorMedix at Outperform With $18 Price Target	MT
19/12/24	RBC Raises Price Target on CorMedix to $12 From $11, Keeps Outperform, Speculative Risk	MT
22/10/24	Truist Raises Price Target on CorMedix to $17 From $12, Keeps Buy Rating	MT
25/07/24	Truist Adjusts CorMedix's Price Target to $12 From $14, Maintains Buy Rating	MT
13/03/24	RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier	MT
15/11/23	RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk	MT
10/08/23	RBC Initiates CorMedix at Outperform, Speculative Risk With $6 Price Target, Sees DefenCath 'More Likely Than Not to Be Approved'	MT
19/05/23	JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating	MT
01/03/23	JMP Securities Adjusts CorMedix's Price Target to $16 From $14, Keeps Market Perform Rating	MT

More recommendations

Specialty & Advanced Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CORMEDIX INC.					+95.33%
	ELI LILLY AND COMPANY					+4.56%
	JOHNSON & JOHNSON					+5.91%
	ABBVIE INC.					-0.3%
	ROCHE HOLDING AG					-1.29%
	MERCK & CO., INC.					+9.97%
	NOVARTIS AG					-3.4%
	ASTRAZENECA PLC					+22.47%
	AMGEN INC.					-9.69%
	GILEAD SCIENCES, INC.					+2.66%
	Average					+12.62%
	Weighted average by Cap.					+3.78%